Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Grossi

Neurological Surgery Raleigh, NC Medical Doctor

NPI 1881863744 CMS profile 40875

3480 Wake Forest Rd, Suite 500, Raleigh, NC 27609

Open in the dashboard

General payments

$149,235

234 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$27,052

1 holding reported · through program year 2025

Through program year 2025, Peter Grossi of Raleigh, NC is reported in the CMS Open Payments database as having received $149,235 across 234 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $27,052 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,362 27
2024 General $17,022 30
2023 General $11,111 25
2022 General $34,824 53
2021 General $28,231 25
2020 General $21,706 30
2019 General $32,980 44
2025 Ownership $27,052 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Grossi
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Peter Grossi were reported at $3,362. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Peter Grossi Neurological Surgery median Middle half National median
2019 $32,980 $582 $138–$3,006 $163
2020 $21,706 $294 $76–$2,174 $114
2021 $28,231 $387 $105–$2,432 $132
2022 $34,824 $542 $139–$2,989 $149
2023 $11,111 $534 $145–$2,697 $160
2024 $17,022 $574 $155–$3,046 $164
2025 $3,362 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $101,621 79 payments
  2. DePuy Synthes Products, Inc. $17,134 19 payments
  3. CoreLink, LLC $8,027 6 payments
  4. Pacira Pharmaceuticals Incorporated $7,526 5 payments
  5. NuVasive, Inc. $3,349 25 payments
  6. Zavation LLC $2,080 2 payments
  7. Tricoast Surgical Solutions LLC $1,823 12 payments
  8. Globus Medical, Inc. $1,199 8 payments
  9. Arthrex, Inc. $1,120 8 payments
  10. DePuy Synthes Sales Inc. $1,075 21 payments
  11. Other $4,281 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $118,440 25 payments
  2. Travel and Lodging $17,679 58 payments
  3. Food and Beverage $7,355 145 payments
  4. Royalty or License $5,687 5 payments
  5. Entertainment $75 1 payment
Products named General payments · program years 2019–2025
  1. VIPER Spine $36,500 15 payments
  2. VIPER Spine $35,772 34 payments
  3. CONCORDE Spine $34,063 18 payments
  4. COUGAR Spine $32,370 10 payments
  5. ViviGen $32,331 9 payments
  6. CONDUIT $26,670 10 payments
  7. Sentio $26,277 6 payments
  8. COUGAR Spine $26,277 6 payments
  9. CONCORDE Spine $9,984 4 payments
  10. Vivigen MIS Delivery System $9,869 3 payments
  11. Other $20,660 107 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$127,392

Medicare's payments for the services billed

Medicare patients

192

Average age 73

Services billed

518

100 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 29%
Depression 29%
Diabetes 25%
Chronic kidney disease 20%
Cancer 20%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $380
$380 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $380
$380 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

234 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record